| Drug General Information |
| Drug ID |
D0Q5ZJ
|
| Former ID |
DNC000182
|
| Drug Name |
Alpha-estradiol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H24O2
|
| Canonical SMILES |
CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
|
| InChI |
1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17-,18+/m1/s1
|
| InChIKey |
VOXZDWNPVJITMN-SFFUCWETSA-N
|
| CAS Number |
CAS 57-91-0
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5544, 82900, 8139857, 8143675, 8192210, 11364694, 11367256, 11369818, 11372859, 11375418, 11377981, 12146107, 14897274, 15221951, 22391544, 24702251, 24894682, 26755326, 26755327, 43125123, 46488040, 47217073, 48421883, 49688698, 50087220, 50473417, 51091460, 56310604, 57316935, 57392211, 91704112, 92298710, 92721154, 93165615, 103097915, 104234168, 104342496, 124892354, 124892355, 126523270, 126619403, 129506091, 134971198, 135727368, 137003335, 139780840, 144208460, 144213948, 162228627, 163138824
|
| ChEBI ID |
ChEBI:17160
|
| Target and Pathway |
| Target(s) |
Androgen receptor |
Target Info |
Antagonist |
[1]
|
|---|
|
KEGG Pathway
|
Oocyte meiosis
|
|
Pathways in cancer
|
|
Prostate cancer
|
|
NetPath Pathway
|
EGFR1 Signaling Pathway
|
|
AndrogenReceptor Signaling Pathway
|
|
FSH Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Coregulation of Androgen receptor activity
|
|
Regulation of Androgen receptor activity
|
|
Nongenotropic Androgen signaling
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FOXA1 transcription factor network
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
Nuclear Receptor transcription pathway
|
|
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33. |
|---|
